AbstractBackground and Objective The cytochrome P450 (CYP) system plays a central role in drug metabolism and pharmacokinetic variability, influencing drug–drug interaction risk. The newly synthesized 4-propoxy-2-arylquinoline derivatives (MW1–3) are dual inhibitors of epidermal growth factor receptor (EGFR) and focal adhesion...
Resistance to anti-EGFR therapy remains a major challenge in head and neck squamous cell carcinoma (HNSCC), as adaptive mechanisms driven by drug-tolerant persister cells (DTPs) ultimately compromise treatment efficacy. Here, we identify Interleukin-1 (IL-1)-mediated inflammation as a critical driver of...
Open AccessArticle LL-37 Inhibits EV71 Infection by Upregulating STAC via the EGFR-ERK Signaling Pathway by Jiaqi ZhangJiaqi Zhang SciProfiles Scilit Preprints.org Google Scholar 1,2,†, Hanlin ZhangHanlin Zhang SciProfiles Scilit Preprints.org Google Scholar 3,†, Yi ChenYi Chen SciProfiles Scilit Preprints.org Google...
AbstractPurpose of Review This review examines the mechanisms of acquired resistance to third-generation EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). While genetic bypass mutations are well-understood, the focus here is on lineage plasticity-a non-genetic process where...
Background Leptomeningeal metastasis (LM) after the development of third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance is indicative of a poor prognosis in EGFR-mutant non-small cell lung cancer (NSCLC), and no standardised treatments are currently available. The aims...
David Planchard: New Chinese Study Results on ADCs in EGFR-Mutant NSCLC Waleed Arafat, Professor of Clinical Oncology at University of Alexandria, shared a post on LinkedIn by David Planchard, Thoracic Oncologist, Professor at the University Paris Saclay and Head of...
COCOON trial shows proactive skin care can halve dermatologic toxicity in EGFR-mutant NSCLC BUFFALO, NY - April 3, 2026 - A new research perspective was published in Volume 13 of Oncoscience on March 11, 2026, titled “Early success of the...
Open AccessReview EGFR Signaling in Colorectal Cancer: Novel Therapeutic Strategies, Predictive Biomarkers, and Counteracting Treatment Resistance by Noura AbbasNoura Abbas SciProfiles Scilit Preprints.org Google Scholar , Mohamad MouradMohamad Mourad SciProfiles Scilit Preprints.org Google Scholar , Hiba SmailyHiba Smaily SciProfiles Scilit...
The epidermal growth factor receptor (EGFR) is a well-established oncogenic driver in multiple epithelial cancers, yet its role in breast cancer remains elusive, with EGFR-targeted therapies showing limited clinical efficacy. Here, we demonstrate that EGFR promotes selective lymphatic dissemination in...
